Skip to main content

Biogen news in 2026: 19 dated events

The latest Biogen event on this page is dated Oct 2, 2026. globenewswire.com reported: Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class...

Public (BIIB)Biotechnology Research10,000+ employeesbiogen.comLinkedIn

Get Biogen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Biogen this week? Use Autobound signals for biogen.com.
Dated events
20
Last 90 days
7
Latest
Oct 2, 2026

Source: Autobound Signal API · 76 signals tracked for Biogen · updated

News · latest 10

Latest Biogen news

  1. In development
    Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class...Biogen announced 52-week results from the Phase 2 part of its ongoing AMETHYST Phase 2/3 study for litifilimab, a potential first-in-class therapy for cutaneous lupus erythematosus (CLE), showing rapid and durable efficacy.
  2. Launch
    Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents...Biogen announced the publication of results from a Phase 3 study of its drug EMPAVELI® (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology.
  3. Launch
  4. Recognition
    Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s DiseaseBiogen's drug LEQEMBI® (lecanemab) received a final positive recommendation supporting public reimbursement for early Alzheimer’s disease from Canada’s Drug Agency (CDA-AMC).
  5. Integration
  6. Acquisition
    Biogen Completes Acquisition of Ray TheraBiogen has completed its acquisition of Ray Thera, a private biotechnology company, in a deal valued at up to $1 billion.
  7. Acquisition
    Biogen Completes Acquisition of RayThera Inc.Biogen has completed its acquisition of RayThera Inc., a biotechnology company focused on immunology therapies.
  8. Revenue
    Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease PortfolioBiogen reported revenues of $2.736 billion, beating the consensus of $2.458 billion.
  9. Earnings
    Biogen reports Q2 2026: $2.74B revenue, GAAP EPS $0.66, Non‑GAAP EPS $3.60Biogen reported second-quarter 2026 GAAP diluted EPS of $0.66 and non-GAAP diluted EPS of $3.60.
  10. Partnership

Showing 10 of 20 dated events. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Biogen with the Signal API

One POST /v1/companies/enrich call with biogen.com returns Biogen news signals (news), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","signal_types":["news"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.

Talk to sales

Same industry

Questions about Biogen news

What is the latest news on Biogen?
The newest event on this page is dated Oct 2, 2026. globenewswire.com reported: Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class.... This page lists 20 dated events for Biogen, each with a source link.
What is going on with Biogen?
The 10 latest events on this page cover in development (1), launch (2), recognition (1), integration (1), acquisition (2), revenue (1), earnings (1) and partnership (1). The newest: Oct 2, 2026: Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class... (globenewswire.com).

Page updated , the date of the newest row on this page.

Source. News articles about the company, one source link per event.

Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.

Data as of .

How this data is built →Get it from the Signal API →